Client News

Posted: August 26, 2016, 4:00 pm
[Business Wire] - OPKO Health, Inc. , announces that at a Special Shareholder Meeting held on August 25, 2016 shareholders of Transition Therapeutics, Inc. holding approximately 93% of the outstanding common shares, voted to approve the previously announced agreement under which OPKO Health will acquire Transition Therapeutics.
Posted: August 26, 2016, 12:52 pm
[CNW Group] - Transition Therapeutics Announces Special Shareholder Meeting Voting Results Including Shareholder Approval of the Plan of Arrangement with OPKO Health, Inc.
Posted: August 25, 2016, 10:46 pm
[PR Newswire] - TORONTO, Aug. 25, 2016 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) is pleased to announce that the Company has received shareholder approval for the previously announced plan of arrangement involving Transition, OPKO Health, Inc., OPKO Global Holdings, Inc. and the Transition Shareholders (the "Arrangement"). A total of 24,586,901 common shares, approximately 63.4% of the outstanding common shares, were represented at the meeting of Transition Shareholders (the "Meeting") in person or by proxy. The Arrangement was approved by shareholders holding approximately 92.9% of the common shares of Transition who voted on the Arrangement in person or by proxy at the Meeting.
Posted: August 25, 2016, 10:46 pm
[at noodls] - PRESS RELEASE BC PDGF did not meet the primary endpoint in this Phase 3 trial conducted in India BC PDGF was confirmed to be safe and well tolerated Lyon, August 25 2016 - Adocia (Euronext Paris: FR0011184241 ...
Posted: August 25, 2016, 4:08 pm
Posted: August 24, 2016, 5:04 pm
[at noodls] - BOTHELL, Wash., Aug. 24, 2016/PRNewswire / -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and ...
Posted: August 24, 2016, 10:28 am
[PR Newswire] - BOTHELL, Wash., Aug. 24, 2016 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"), today announced that its clinical grade CryoStor freeze media has been incorporated into the manufacturing process for Invossa, a cell-mediated gene therapy for knee osteoarthritis to be marketed by Kolon Life Science. According to Kolon, Invossa is the world's first cell-mediated gene therapy for osteoarthritis, a degenerative joint disease affecting more than 150 million people.
Posted: August 24, 2016, 10:00 am
Posted: August 23, 2016, 9:07 pm
Posted: August 23, 2016, 5:27 pm
Posted: August 23, 2016, 5:04 pm